Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck

Strahlentherapie und Onkologie

Volumn 189, Issue 8, 2013, Pages 625-631

  Matuschek, C ^a   Bolke E ^a   Belka, C ^b   Ganswindt, U ^b   Henke, M ^c   Stegmaier, P ^c   Bamberg, M ^d   Welz, S ^d   Debus, J ^e   Gioules, A ^e   Voigt, A ^f   Volk, G ^f   Ohmann, C ^a   Wiegel, T ^g   Budach, V ^h   Stuschke, M ⁱ   Schipper, J ^a   Gerber, P A ^a   Budach, W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adverse effects; Clinical trial, phase II; Head and neck neoplasms; Interim analysis; Toxicity

Indexed keywords

CETUXIMAB; CISPLATIN; FLUOROURACIL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CANCER INCIDENCE; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE; SKIN MANIFESTATION; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LONGITUDINAL STUDIES; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 84881245112     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0378-2     Document Type: Article

References (24)

1. Al-Sarraf M, Pajak TF, Byhardt RW et al (1997) Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37:777-782
2. Alongi F, Bignardi M, Garassino I et al (2012) Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlenther Onkol 188:49-55
3. Ang K (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29:Abstr. 5500
4. Argiris A, Heron DE, Smith RP et al (2010) Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 28:5294-5300
5. Bernier J (2004) Canc EORT. Treatment of advanced head and neck cancer - Reply. N Engl J Med 351:830-831
6. Bolke E, Gerber PA, Lammering G et al (2008) Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 184:105-110
7. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28
8. Budach W, Bolke E, Homey B (2007) Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357:514-515
9. Christiansen H, Rodel RM (2012) Neck dissection of the residually positive neck after primary radiochemotherapy for locally advanced head and neck cancer. Strahlenther Onkol 188:444-445
10. Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944
11. Cooper JS, Zhang Q, Pajak TF et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84:1198-1205
12. Cvek J, Kubes J, Skacelikova E et al (2012) Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study. Strahlenther Onkol 188:666-670
13. Fietkau R, Iro H, Grabenbauer GG et al (1991) Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors. Strahlenther Onkol 167:693-700
14. Fietkau R, Iro H, Tulusan AH et al (1994) Prognostic value of S-phase fraction in head and neck squamous cell carcinomas and nodal negative breast carcinomas. Strahlenther Onkol 170:13-24
15. Fietkau R, Lautenschläger C, Sauer R et al (2006) Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: results of the German phase III trial ARO 96-3. J Clin Oncol 24:1
16. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098
17. Giro C, Berger B, Bolke E et al (2009) High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 90:166-171
18. Jordi G, Andre F, Ricard M et al (2012) A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 30:Abstract 5502
19. Karamouzis MV, Grandis JR, Argiris A (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298:70-82
20. Milas L, Mason K, Hunter N et al (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708
21. Specenier P, Vermorken JB (2011) Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 11:511-524
22. Thariat J, Milas L, Ang KK (2007) Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69:974-984
23. Vermorken JB, Guigay J, Mesia R et al (2011) Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104:1691-1696
24. Vermorken JB, Remenar E, Herpen C van et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704